Associations - JAK2 (Janus kinase 2)

CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
JAK2 mutation	Acute Myelogenous Leukemia	JAK2 mutation	Acute Myelogenous Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
JAK2 mutation	Leukemia	JAK2 mutation	Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
JAK2 mutation	Acute Myelogenous Leukemia	JAK2 mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
JAK2 deletion	Non Small Cell Lung Cancer	JAK2 deletion	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	TL-1-85 Sensitive: C3 – Early Trials TL-1-85 Sensitive : C3	TL-1-85 Sensitive: C3 – Early Trials TL-1-85 Sensitive : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	QL-VIII-58 Sensitive: C3 – Early Trials QL-VIII-58 Sensitive : C3	QL-VIII-58 Sensitive: C3 – Early Trials QL-VIII-58 Sensitive : C3
JAK2 amplification	Non Small Cell Lung Cancer	JAK2 amplification	Non Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	fedratinib Resistant: C3 – Early Trials fedratinib Resistant : C3	fedratinib Resistant: C3 – Early Trials fedratinib Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3
JAK2 rearrangement	Chronic Myeloid Leukemia	JAK2 rearrangement	Chronic Myeloid Leukemia	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
PCM1-JAK2 fusion	Chronic Myeloid Leukemia	PCM1-JAK2 fusion	Chronic Myeloid Leukemia	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
PCM1-JAK2 fusion	Chronic Eosinophilic Leukemia	PCM1-JAK2 fusion	Chronic Eosinophilic Leukemia	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
PD-L1 expression + JAK2 mutation	Cervical Cancer	PD-L1 expression + JAK2 mutation	Cervical Cancer	anlotinib + sintilimab Resistant: C3 – Early Trials anlotinib + sintilimab Resistant : C3	anlotinib + sintilimab Resistant: C3 – Early Trials anlotinib + sintilimab Resistant : C3
PD-L1 expression + STK11 mutation + JAK2 mutation	Cervical Cancer	PD-L1 expression + STK11 mutation + JAK2 mutation	Cervical Cancer	anlotinib + sintilimab Resistant: C3 – Early Trials anlotinib + sintilimab Resistant : C3	anlotinib + sintilimab Resistant: C3 – Early Trials anlotinib + sintilimab Resistant : C3
JAK2 mutation + MSI-H/dMMR	Colorectal Cancer	JAK2 mutation + MSI-H/dMMR	Colorectal Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
JAK2 V617F	Acute Myelogenous Leukemia	JAK2 V617F	Acute Myelogenous Leukemia	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4
JAK2 F547	Melanoma	JAK2 F547	Melanoma	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4
JAK2 F547	Melanoma	JAK2 F547	Melanoma	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4
GOLGA5-JAK2 fusion	B Acute Lymphoblastic Leukemia	GOLGA5-JAK2 fusion	B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: C4 – Case Studies ruxolitinib Sensitive : C4	ruxolitinib Sensitive: C4 – Case Studies ruxolitinib Sensitive : C4
STRBP-JAK2 fusion	B Acute Lymphoblastic Leukemia	STRBP-JAK2 fusion	B Acute Lymphoblastic Leukemia	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4
STRBP-JAK2 fusion	B Acute Lymphoblastic Leukemia	STRBP-JAK2 fusion	B Acute Lymphoblastic Leukemia	ruxolitinib Resistant: C4 – Case Studies ruxolitinib Resistant : C4	ruxolitinib Resistant: C4 – Case Studies ruxolitinib Resistant : C4
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22)	B Acute Lymphoblastic Leukemia	RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22)	B Acute Lymphoblastic Leukemia	ruxolitinib Resistant: C4 – Case Studies ruxolitinib Resistant : C4	ruxolitinib Resistant: C4 – Case Studies ruxolitinib Resistant : C4
JAK2 F694L	B Acute Lymphoblastic Leukemia	JAK2 F694L	B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: C4 – Case Studies ruxolitinib Sensitive : C4	ruxolitinib Sensitive: C4 – Case Studies ruxolitinib Sensitive : C4
JAK2 V617F	Acute Myelogenous Leukemia	JAK2 V617F	Acute Myelogenous Leukemia	CPI-482 Sensitive: D – Preclinical CPI-482 Sensitive : D	CPI-482 Sensitive: D – Preclinical CPI-482 Sensitive : D
JAK2 overexpression	Diffuse Large B Cell Lymphoma	JAK2 overexpression	Diffuse Large B Cell Lymphoma	EUD-GK-001 Sensitive: D – Preclinical EUD-GK-001 Sensitive : D	EUD-GK-001 Sensitive: D – Preclinical EUD-GK-001 Sensitive : D
PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
IGH-CRLF2 fusion + JAK2 R867Q	Childhood B Acute Lymphoblastic Leukemia	IGH-CRLF2 fusion + JAK2 R867Q	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
IGH-CRLF2 fusion + JAK2 R683G	Acute Lymphocytic Leukemia	IGH-CRLF2 fusion + JAK2 R683G	Acute Lymphocytic Leukemia	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D
IGH-CRLF2 fusion + JAK2 GPInsR683	Childhood B Acute Lymphoblastic Leukemia	IGH-CRLF2 fusion + JAK2 GPInsR683	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D

JAK2 (Janus kinase 2)

Associations(48)

Associations
(48)